| MAR |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.09 vs. cons $3.04 |
MEDIUM |
| MAR |
Report |
Worldwide constant-dollar RevPAR growth |
BEAT |
pred ~2.4% vs. cons 2.1% |
MEDIUM |
| MAR |
Report |
Gross fee revenue |
IN-LINE |
pred ~$1.555B vs. cons $1.548B |
MEDIUM |
| MAR |
Guide |
FY26 worldwide constant-dollar RevPAR growth |
UNCHANGED |
guide ~2.5% vs. cons 2.5% (FY26) |
MEDIUM |
| MAR |
Guide |
FY26 adjusted EBITDA |
UNCHANGED |
guide ~$5.93B vs. cons $5.94B (FY26) |
MEDIUM |
| MAR |
Guide |
FY26 adjusted diluted EPS |
UNCHANGED |
guide ~$11.55 vs. cons $11.54 (FY26) |
MEDIUM |
| MAR |
Guide |
FY26 net rooms growth |
UNCHANGED |
guide ~4.75% vs. cons 4.75% (FY26) |
HIGH |
| MAR |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.0% |
— |
MEDIUM |
| MAR |
Return |
5-day cumulative residual |
+1.2% (STABILIZE) |
A modest EPS and RevPAR beat should support an initial positive reaction, but maintained FY26 RevPAR, EBITDA, and EPS outlooks imply little upward out-period estimate math; the stock should retain most of the gain rather than materially extend it. |
MEDIUM |